TY - JOUR
T1 - The role of OCT-A in retinal disease management
AU - On behalf of the Vision Academy Steering Committee
AU - Rodríguez, Francisco J.
AU - Staurenghi, Giovanni
AU - Gale, Richard
AU - Eldem, Bora
AU - Hunyor, Alex
AU - Joussen, Antonia
AU - Koh, Adrian
AU - Korobelnik, Jean François
AU - Lanzetta, Paolo
AU - Loewenstein, Anat
AU - Lövestam-Adrian, Monica
AU - Navarro, Rafael
AU - Okada, Annabelle A.
AU - Pearce, Ian
AU - Rodríguez, Francisco J.
AU - Wolf, Sebastian
AU - Wong, David T.
N1 - Publisher Copyright:
© 2018, The Author(s).
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Optical coherence tomography angiography (OCT-A) is a non-invasive, non-dye-based imaging modality that has the potential to enhance our understanding of retinal diseases. While this rapidly advancing imaging modality offers great potential, there is a need for community-wide understanding of the range of technologies and methods for interpreting the images, as well as a need to enhance understanding of images from disease-free eyes for reference when screening for retinal diseases. Importantly, clinical trials have been designed without OCT-A-based endpoints; therefore, caution is required when making treatment decisions based on OCT-A imaging alone. With this in mind, a full understanding of the advantages and limitations of OCT-A will be vital for effective development of the technique within the field of ophthalmology. On behalf of the Vision Academy Steering Committee (sponsored by Bayer), this publication summarizes the views of the authors on the current use of OCT-A imaging and explores its potential for future applications in research and clinical practice.
AB - Optical coherence tomography angiography (OCT-A) is a non-invasive, non-dye-based imaging modality that has the potential to enhance our understanding of retinal diseases. While this rapidly advancing imaging modality offers great potential, there is a need for community-wide understanding of the range of technologies and methods for interpreting the images, as well as a need to enhance understanding of images from disease-free eyes for reference when screening for retinal diseases. Importantly, clinical trials have been designed without OCT-A-based endpoints; therefore, caution is required when making treatment decisions based on OCT-A imaging alone. With this in mind, a full understanding of the advantages and limitations of OCT-A will be vital for effective development of the technique within the field of ophthalmology. On behalf of the Vision Academy Steering Committee (sponsored by Bayer), this publication summarizes the views of the authors on the current use of OCT-A imaging and explores its potential for future applications in research and clinical practice.
KW - Imaging modality
KW - Non-invasive
KW - OCT-A
KW - Optical coherence tomography angiography
KW - Retinal diseases
UR - http://www.scopus.com/inward/record.url?scp=85052843613&partnerID=8YFLogxK
U2 - 10.1007/s00417-018-4109-3
DO - 10.1007/s00417-018-4109-3
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 30175386
AN - SCOPUS:85052843613
SN - 0721-832X
VL - 256
SP - 2019
EP - 2026
JO - Graefe's Archive for Clinical and Experimental Ophthalmology
JF - Graefe's Archive for Clinical and Experimental Ophthalmology
IS - 11
ER -